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INTRODUCTION
The field of stem cell transplantation continues to
advance very rapidly (1). The term “bone marrow
transplantation" now has become less used. Instead
of bone marrow cells, peripheral blood stem cells
(PBSC), or cord blood cells are increasingly used
for hematopoietic rescue operations. In the 1980 s,
we recognized that hematopoietic progenitor cells
circulated in the blood during the marrow recovery
phase of myelosuppressive chemotherapy and could be
concentrated for transplantation by repeated aphereses
(2, 3). Thereafter hematopoietic growth factors came into
clinical use, which markedly improved the efficiency of
PBSC collection and accelerated hematopoietic recovery
following transplantation (4). Over the last decade, the use
of PBSC and better supportive care techniques have made
high-dose chemotherapy comparatively safe with less than
a 2-3% mortality rate in experienced centers (5). Thus, it
has now been widely applied even in community hospitals
(6). Recently, PBSC also began to be applied as an
allogeneic stem cell source for the treatment of
hematologic malignancies (7). Nonetheless, the exact
mechanism of stem cell mobilization is poorly understood,
and the biology of PBSC remains incompletely defined. In
this review, we update recent progress in this field.
PERIPHERAL BLOOD AS A STEM CELL SOURCE
Mobilization
There is little question against the need to mobilize
progenitor/stem cells for practical collection. Mobilization
of progenitor cells from the bone marrow (BM) to
the PB can be achieved with myelosuppressive chemo-
therapy alone, or in combination with hematopoietic
growth factors, or with hematopoietic growth factor
alone administered in an hematologic steady state.
Myelosuppressive chemotherapy was the first measure
used for mobilization (8). In this way the timing of
apheresis is rather unpredictable and toxicities such as
neutropenic fever are inevitable (9). With the advent of
growth factors, myelosuppressive chemotherapy alone
is less used for mobilization. Mobilization methods by
growth factors alone are certainly more convenient since
collection days can be more precisely timed. Granulocyte
colony-stimulating factor (G-CSF) or granulocyte/
macrophage colony-stimulating factor (GM-CSF) alone
enhance mobilization in both cancer patients and normal
healthy donors (10, 11). In the allogeneic setting, G-CSF
is exclusively used because its administration is safer and
less toxic compared with other available cytokines
including GM-CSF (12). Other cytokines or combinations
of current or new growth factors, i.e., stem cell factor,
interleukin-3 and thrombopoietin, are being studied as
more efficient mobilizers (13). However, additional
advantages of these factors to G-CSF are still unknown.
The exact mechanism by which progenitor cells are
mobilized is unknown. Evidence is now emerging that cell
adhesion molecules (CAMs) may be involved in the
process of mobilization (14, 15). We studied several CAM
expressions on PB and BM CD 34+ cells and found a
significantly lower expression of integrins such as very
late antigen-4 (VLA-4), leukocyte function antigen-1
(LFA-1) and LFA-3, and a significantly higher expression
of L-selectin and CD44 on PB CD34+ cells compared with
BM CD34+ cells. This suggests that decreased expression
of CAMs play a role in progenitor cell mobilization.
Progenitor cell mobilization might occur as a stochastic
process and involve the selection of CD34+ cell with low
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CAMs. Some role might be attributed to a loss of function
of integrins, and the disruption of VLA-4 ligand receptor
binding results in the release of progenitor cells in
primates (16).
Collection and storage
Cell separators widely used for PBSC collections are
Spectra (Cobe Laboratories), CS 3000 (Baxter Health
Care Corp.) and AS 104 (Fresenius AG). Harvesting PBSC
is safe and does not involve the risk of general anesthesia
(17) or multiple invasive marrow aspirations. Adverse
effects related to apheresis procedures occurred in
less than 3% of adults (18). These included moderate
hypovolemia and symptomatic hypocalcemia with perioral
paresthesia which usually promptly resolved with infusion
of calcium gluconate.
For cryopreservation of PBSC, a simple freezing
method using 6% hydroxyethyl starch (HES), 5% dimethyl
sulfoxide (DMSO) and 4% albumin has been used (19).
This procedure is simple and requires less processing
time compared with the conventional method which
employs controlled-rate freezing by a programmed freezer
and use of 10% DMSO (20). For storage of PBSC, a-135℃
mechanical freezer replaced the storage in liquid nitrogen
at some transplant centers. PBSC isolated from apheresis
products can be stored in a-80℃ mechanical freezer, but
the duration of frozen storage should not exceed 1.5 years
(21).
Monitoring PBSC collection efficiency
Colony forming units-granulocyte/macrophage (CFU-
GM) and CD34+ cells are the two widely accepted
indicators of the hematopoietic reconstitutive capacity of
transplanted cells. The dose-effect relationship between
the CFU-GM content of the graft and the speed of
recovery following PBSCT has been shown in several
studies(22). Standardization of CFU-GM measurements
remains elusive due to the variations in methodology used
in different laboratories. The measurement of CD34+ cells
using a flow cytometer is much quicker than CFU-GM
assays, which require at least 2 weeks to obtain the final
results (23). However, CD34+ cell enumeration needs the
level of stringency to measure rare event at the level of
0.1% to 3% (9). Issues in achieving standardization in
CD34+ cell enumeration include gating strategy, CD34
antibody and degree of cell debris (24).
Characterization of PBSC
The phenotypic analyses of mobilized CD34+ cells are
also extensively studied. The most striking differences
observed regarding phenotypic profiles of mobilized
CD34+ cells were the very high percentage of CD34+ cells
coexpressing CD33 and CD13 molecules and the low
percentage coexpressing CD10 and CD19 compared
with BM CD34+ cells (25). Furthermore, PB CD34+
cells express less c-kit and CD71, suggesting that
the mobilization of progenitor cells involves the
down-regulation of c-kit (8). Mobilized PBSC showed a
low percentage of circulating cells in the S phase despite
growth factor administration. This may be due to a
selective release from BM cells in the G0-G1 phase and/or
to the expression of critical cell cycle-related adhesion
receptors.
AUTOLOGOUS TRANSPLANT
Initially, PBSCT was used for patients who were not
eligible for BM harvest because of tumor involvement,
extensive marrow fibrosis following local irradiation or
contraindication to general anesthesia (1). Although
there was a concern regarding long-term hematopoiesis
following PBSCT, recent clinical data supported the
durability of normal hematopoiesis after autografting with
PBSC. Furthermore, proof of long-term engraftment
following infusion of PBSC was obtained by gene-marking
studies (26, 27). Since 1990, the number of PBSCT has far
exceeded that of BMT in the autologous setting, and
nowadays, PBSC have been used in 90% of autologous
transplants (28). The major advantage of using PBSC over
BM cells is the rapid hematopoietic reconstitution, which
results in a shorter duration of antibiotic use, fewer blood
product transfusions and early hospital discharge.
Although autologous PBSCT should not by themselves
lead to a different tumor control outcome than autologous
BMT. Various analyses show no advantage of PBSCT over
BMT in terms of overall survival rate [Table 1] (29-34).
However, economic assessments of PBSCT have proven a
direct cost saving effect associated with a reduction in the
duration of hospitalization compared with BMT (35, 36).
In some cases, PBSCT are performed largely on an
outpatient basis to save admission costs (37). In addition,
the collection process for PBSC is less invasive than BM
harvest, and the donor can avoid general anesthesia.
PBSCs may be harvested in an outpatient setting. These
properties may increase the pool of unrelated donors in
allogeneic transplants.
Indications for autologous PBSCT have changed with
time and the types of illnesses treated with this approach
continue to increase, within a range of chemosensitive
tumors. High-dose therapy with PBSCT has become an
established therapeutic option for patients with relapsed,
but still chemotherapy-sensitive aggressive non-Hodgkin's
lymphomas (NHL) (5). PBSCT has also been shown to
produce long-term disease-free survival in selected
patients with refractory and advanced Hodgkin's disease
(38). Intensified treatment with high-dose melphalan
supported by PBSC as a means of overcoming drug
resistance yields complete remission even in patients with
high-risk and advanced multiple myeloma (39). Yet,
earlier transplantation is recommended before the
development of drug resistance and end organ damage.
Breast cancer has now become the disease most
frequently treated with autologous PBSCT worldwide
(40). Leading indications moved from refractory or
metastatic breast cancer to high-risk or locally advanced
breast cancer as an adjuvant consolidative therapy. Germ
cell tumors are also a good indication for autologous
PBSCT. Although autologous PBSCT also has been
performed for childhood cancers such as neuroblastoma,
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rabdomyosarcoma and Wilms' tumor, the number of cases
is still small and its role for these indications remains to
be determined. For acute leukemias, many trials involving
autologous BMT or PBSCT have been performed in
patients with AML.
Dose intensification and sequential use of agents to
overcome drug resistance may benefit some patients,
and interest in the concept of tandem transplants has
been growing. The principal objective of this procedure
is to reduce the size of a slowly growing tumor mass
by repeated, closely timed courses of high-dose
chemotherapy, each given with hematopoietic stem cell
rescue. Tandem cycles of high-dose chemotherapy
became feasible with autologous PBSCT, since abundant
PBSC yields obtained by apheresis provides the
opportunity to deliver more than one cycle of high-dose
chemotherapy. These procedures are under intense
investigation in the treatment of breast cancer, childhood
cancers and multiple myeloma (41-43).
ALLOGENEIC TRANSPLANT
G-CSF mobilized allogeneic PBSC have been used
without significantly increased severe GVHD while
reproducing the rapid reconstitution seen in the
autologous setting (44). A number of recent studies
indicated that transplants using allogeneic PBSC had an
obvious advantage for accelerated engraftment over
conventional BMT (45). Although there was concern that
a relatively high number of infused lymphocytes might
result in unacceptably severe acute GVHD, this has not
been observed in fully matched sibling pairs (46). The
early survival rates were similar between allogeneic
PBSCT and BMT [Table 1] (44,45). Nevertheless, there is
a possibility that the risk of chronic GVHD may increase
in allogeneic PBSCT (47).
Regarding stem-cell mobilization in normal donors, two
clinical variables should be taken into consideration. The
first is efficacy, defined as the ability to mobilize sufficient
numbers of PBSC, and the second is toxicity, defined as
the side effects that the donor may experience. Although
Table 1. Comparative studies of PBSCT vs BMT
Ref. : References, NHL : Non-Hodgkin's lymphoma, HD : Hodgkin's disease, AML : acute myelogeneous leukemia, ALL : acute lymphocytic
leukemia, CML : chronic myelogenous leukemia, CLL : chronic lymphocytic leukemia, MDS : myelodysplastic syndrome, MPD :
myeloproliferative disorder, MM : multiple myeloma, EGBMT : the European Group for Blood and Marrow Transplantation, CR : complete
remission, PR : partial remission, N.S. : not significant
Ref. Type of
transplant
Disease Investigator
/Type of study
Timing Overall survival
(PBSCT vs BMT)
Advantages of PBSCT
over BMT
29 Auto Follicular NHL
(n=60)
Bastion, et al./
Comparison with
published data
Variable
Mostly PR
86% (2 yr.) vs
50% (5 yr.)
Low treatment-
related death rate
30 Auto HD & NHL
(n=27 vs 31)
Schmitz N, et al.
/Prospective
randomized
Variable 87.1% vs 88.9%
p=N. S.
(median follow-
up ; 311 days)
Rapid hematopoietic
reconstitution
Early discharge from
hospital
31 Auto HD
(n=227 vs 227)
EGBMT/
Randomized
Variable 52.7% vs 65.3%
p=.0198
(4 yrs)
Rapid hematopoietic
reconstitution
31 Auto NHL
(n=128 vs 128)
EGBMT/
Randomized
Variable 52.7% vs 56.6%
p=.4148
(4 yrs)
Rapid hematopoietic
reconstitution
32 Auto Adult ALL
(n=12 vs 38)
Powles R, et al./
Non-randomized
First CR 11/12 vs 21/38
(median follow-up ;
40 months)
Decreased transplant-
related toxicity
33 Auto Multiple
myeloma
(n=43 vs 43)
Harousseau JL, et al./
Randomized
First
remission
induction
45% vs 45%
p=0.37
(4 yrs)
Neutrophil recovery
34 Auto Germ cell tumor
(n=23 vs 24)
Beyer J, et al./
Randomized
Relapsed
or
refractory
41.7% vs 52.2%
p=0.39
Rapid hematopoietic
reconstitution
45 Allo AML, ALL,
CML, CLL,
MDS, MPD,
NHL, MM
(n=22 vs 21)
Pavletic ZS, et al./
Prospective
randomized
Variable 83% vs 75%
(100 day )
p=0.358
Faster engraftment,
Shorter hospital stay
44 Allo AML, NHL,
ALL, HD,
CML, MM
(n=37 vs 37)
Bensinger WI, et al./
Retrospective
comparison
Relapse or
>CR 2
50% vs 41%
(estimated at 285
days)
p=0.39
Faster engraftment,
Fewer transfusions,
No greater incidence
of acute or chronic
GVHD
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mobilization with G-CSF thus far seems a safe procedure
for normal donors, most donors still complain of general
fatigue and myalgias/arthralgias which are relieved easily
by analgesia. The platelet count decreased in most
donors. Slight but significant decrease in platelet count is
observed at the peak of the G-CSF induced leukocytosis.
It is suggested that G-CSF administration reduced the
capacity for platelet production (48). Furthermore, a
decrease in platelet count was subsequently enhanced by
an apheresis-related decrease. Although there has been
no clinical report of life threatening bleeding, all donors
should be carefully monitored. Another concern
regarding donor safety is the potential long-term toxicities
of G-CSF, which have to be determined with longer
follow-up. The theoretical risk of developing leukemia and
myelodysplastic syndrome (MDS) after G-CSF treatment
may be of concern, but to date, there were insufficient
cohorts to evaluate this possible risk (49). The issues still
to be determined include more detailed knowledge of
G-CSF dosage, optimal PBSC numbers, the dynamics and
durability of engraftment and immunologic reconstitution
of the recipient (50). The superiority of PBSCT over BMT,
particularly from mismatched donors is unproven.
Nowadays, indications for allogeneic PBSCT include
high-risk hematological malignancies such as acute
leukemias, MDS and chronic myelogeneous leukemia.
Non-malignant hematologic disease such as severe
aplastic anemias and congenital immunodeficiencies may
also be good indications for allogeneic PBSCT.
NEW STRATEGIES
CD34 antigen is expressed on both hematopoietic
progenitors and stem cells. The number of progenitor
cells expressing CD34 in PB is known to increase
following mobilization procedures. CD34+ cell purification
technology continues to be improved to obtain cells in
greater than 90% purity and greater than 3-log tumor-cell
or T-cell depletion (51). Purposes of CD34+ cell
purification are to purge tumor cells in the grafts for
autologous PBSCT (52) and to deplete T-cells which
contribute to the development of GVHD in allogeneic
PBSCT (53). In addition, selected CD34+ cells have
the advantage of reducing graft volume, facilitating
storage and decreasing the amount of DMSO as
well as cell lysis products. However, in the autologous
setting clonogenic tumor cells are still present in CD34+
cell selected grafts, and their association with relapse
is unknown. Recent advances in gene marking studies
may provide much-needed information on malignant
contamination in CD34+ selected grafts. Isolex 300 is
now available for clinical use, although the cost of
this equipment for processing exceeds one million yen.
The cost-effectiveness should be evaluated carefully.
Apheresis products undergoing selection of CD34+ cells
have a greater yield and enrichment of progenitor cells
compared with BM harvests collected from HLA-identical
normal healthy donors (54).
Engraftment with CD34+ purified PBSC confirms that
autologous CD34+ cells, alone, are sufficient to provide
hematopoietic rescue for myeloablated patients (55).
Blood cell recovery following CD34+ cell transplantation is
as rapid as after unmanipulated PBSCT, suggesting that
there are no adverse effects to removing accessory cells,
such as activated monocytes or lymphocytes, on blood cell
recovery speed. There is some hope that most patients
can have donors if transplants with allogeneic CD34+ cells
obtained from haploidentical related donors are
performed without deterioration of engraftment and
GVHD. However, there is a concern that major risks of an
allogeneic transplant with CD34+ cells include increased
graft rejection, loss of GVL effect and development of
serious viral infection and lymphoproliferative disorders
due to delayed recovery of immune function (56). In this
regard, add-back of T-cells into patients at an appropriate
time following transplant might be a reasonable strategy.
There is considerable interest in the possibility of
expanding stem cell ex vivo . Ex vivo expansion of
progenitor cells is a new approach to abrogating
cytopenia posttransplant or expanding a small aliquot
of mobilized PBSC to provide sufficient progenitor cells
for hematopoietic rescue. The specific combination of
hematopoietic growth factors and the culture system and/
or hematopoietic stroma were identified as important
variables for ex vivo expansion of PBSC (57). However,
the feasibility of this approach in a clinical setting still
remains unclear in the lack of an in vitro assay for human
stem cells. In addition, whether endogenous tumor cells
from patients are concomitantly expanded in culture
should be monitored carefully in the autologous
transplant setting (58).
Clinical application of gene therapy using PBSC in
patients with cancer or congenital metabolic diseases has
been studied. An advantage of PBSC is that multiple
collection procedures can be performed without invasive
surgery ; which may be an important consideration in
gene therapy (59). The purification of CD34+ cells is again
necessary to improve the transduction and/or long-term
expression.
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